The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates from the PANTHER trial
Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, shares an update on some results from the Phase III PANTHER trial (NCT03268954), which compared the use of azacitidine monotherapy versus azacitidine plus pevonedistat in the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS), chronic myelomonocytic leukemia (CMML), or low-blast acute myeloid leukemia (AML). Dr Sekeres compares some of the main findings of this study, including event-free survival and overall survival, with a previous Phase II trial, and discusses how these results can be used to further improve clinical trials in MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
